Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy.
作者： Awewura Kwara , Margaret Lartey , Kwamena W Sagoe , Michael H Court
DOI: 10.1097/QAD.0B013E3283427E05
关键词: Human immunodeficiency virus (HIV) 、 Medicine 、 CYP2B6 、 Efavirenz 、 Genotype 、 Dose adjustment 、 Analysis of variance 、 Tuberculosis 、 Immunology 、 Drug
摘要: Some individuals have higher efavirenz plasma concentrations during rifampin-containing tuberculosis (TB) therapy, contrary to the expected induction effect of rifampin. Among HIV-infected patients without (n = 38) and with TB on therapy 18), we tested hypothesis that drug-gene interaction may explain highly variable drug interactions. Two-way analysis variance revealed a significant between CYP2B6 516G→T polymorphism suggesting dose adjustment need be individualized basis patient's genotype.
sci-hub.se 参考文章(17)
Chantal Csajka, Catia Marzolini, Karin Fattinger, Laurent A Décosterd, Jacques Fellay, Amalio Telenti, Jérôme Biollaz, Thierry Buclin, Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection Clinical Pharmacology & Therapeutics. ,vol. 73, pp. 20- 30 ,(2003) , 10.1067/MCP.2003.22
Naser L. Rezk, Rustin D. Crutchley, Rosa F. Yeh, Angela D. M. Kashuba, Full validation of an analytical method for the HIV-protease inhibitor atazanavir in combination with 8 other antiretroviral agents and its applicability to therapeutic drug monitoring. Therapeutic Drug Monitoring. ,vol. 28, pp. 517- 525 ,(2006) , 10.1097/00007691-200608000-00006
Luis F. L??pez-Cort??s, Rosa Ruiz-Valderas, Pompeyo Viciana, Aristides Alarc??n-Gonz??lez, Jes??s G??mez-Mateos, Eva Le??n-Jimenez, Maria Sarasanacenta, Yolanda L??pez-Pua, Jer??nimo Pach??n, Pharmacokinetic Interactions Between Efavirenz and Rifampicin in HIV-Infected Patients with Tuberculosis Clinical Pharmacokinectics. ,vol. 41, pp. 681- 690 ,(2002) , 10.2165/00003088-200241090-00004
Paul Brennan-Benson, Richard Lyus, Tom Harrison, Mark Pakianathan, Derek Macallan, Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: one size does not fit all. AIDS. ,vol. 19, pp. 1541- 1543 ,(2005) , 10.1097/01.AIDS.0000183519.45137.A6
Awewura Kwara, Margaret Lartey, Kwamena W. Sagoe, Naser L. Rzek, Michael H. Court, CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients. British Journal of Clinical Pharmacology. ,vol. 67, pp. 427- 436 ,(2009) , 10.1111/J.1365-2125.2009.03368.X
Anne-Sophie Bélanger, Patrick Caron, Mario Harvey, Peter A. Zimmerman, Rajeev K. Mehlotra, Chantal Guillemette, Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Drug Metabolism and Disposition. ,vol. 37, pp. 1793- 1796 ,(2009) , 10.1124/DMD.109.027706
M Lartey, KW Sagoe, A Kwara, CYP2B6, CYP2A6 and UGT2B7 Genetic Polymorphisms are Predictors of Efavirenz Mid-dose Concentration in HIV-infected Patients AIDS. ,vol. 23, pp. 2101- 2106 ,(2009) , 10.1097/QAD.0B013E3283319908
Lars St??hle, Lars Moberg, Jan-Olof Svensson, Anders S??nnerborg, Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects. Therapeutic Drug Monitoring. ,vol. 26, pp. 267- 270 ,(2004) , 10.1097/00007691-200406000-00008
Alberto Matteelli, Mario Regazzi, Paola Villani, Giuseppina De Iaco, Maria Cusato, Anna Cristina Carvalho, Silvio Caligaris, Lina Tomasoni, Maria Manfrin, Susanna Capone, Giampiero Carosi, Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients. Current HIV Research. ,vol. 5, pp. 349- 353 ,(2007) , 10.2174/157016207780636588
K LOBOZ, A GROSS, K WILLIAMS, W LIAUW, R DAY, J BLIEVERNICHT, U ZANGER, A MCLACHLAN, Cytochrome P450 2B6 activity as measured by bupropion hydroxylation : Effect of induction by rifampin and ethnicity Clinical Pharmacology & Therapeutics. ,vol. 80, pp. 75- 84 ,(2006) , 10.1016/J.CLPT.2006.03.010